Predictors of Postoperative Delirium After Transcatheter Aortic Valve Implantation

NCT ID: NCT02585128

Last Updated: 2024-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2021-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients undergoing transcatheter aortic valve implantation (TAVI) have distinctive characteristics: they are old, frail, with several co-morbidities and take multiple medications. Hemodynamic instability, cerebral embolism, sedation, general anesthesia and hospitalization in intensive care expose those patients to postprocedural delirium.

Acute neurocognitive dysfunctions are associated with adverse outcomes in these population.

The objective of this study is to determine the incidence of delirium and neurocognitive disorders in elderly patients after TAVI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients following TAVI

Group Type OTHER

Delirium assessment

Intervention Type OTHER

During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)

MMSE (Mini Mental State Examination)

Intervention Type OTHER

Barthel index

Intervention Type OTHER

HADS (Hospital Anxiety and Depression Scale)

Intervention Type OTHER

MNA-SF (Mini Nutritional Assessment - Short Form)

Intervention Type OTHER

NIRS (Near-Infrared Spectroscopy)

Intervention Type DEVICE

Regional cerebral oxygen saturation monitoring during TAVI procedure

CIRS (Cumulative Illness Rating Scale)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Delirium assessment

During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)

Intervention Type OTHER

MMSE (Mini Mental State Examination)

Intervention Type OTHER

Barthel index

Intervention Type OTHER

HADS (Hospital Anxiety and Depression Scale)

Intervention Type OTHER

MNA-SF (Mini Nutritional Assessment - Short Form)

Intervention Type OTHER

NIRS (Near-Infrared Spectroscopy)

Regional cerebral oxygen saturation monitoring during TAVI procedure

Intervention Type DEVICE

CIRS (Cumulative Illness Rating Scale)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 65\>years
* Patients undergoing transcatheter aortic valve implantation
* Patients have given informed consent for participation at the study

Exclusion Criteria

* Patient suffering from delirium (CAM diagnosis) at recruitment
* Inability to understand the national languages
* Emergency procedures
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardiocentro Ticino

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tiziano Cassina

Tiziano Cassina, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tiziano Cassina, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiocentro Ticino

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiocentro Ticino

Lugano, Canton Ticino, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DELTAVI-CCT-ICU-2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.